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RECENT TRENDS IN INPATIENT DRUG COSTS: 2000–2002
Foster DA
Solucient, LLC, Ann Arbor, MI, USA
OBJECTIVES: To evaluate the extent to which case-mix-
adjusted, hospital inpatient costs for pharmaceutical services
changed from 2000 through 2002 in short-term, general, non-
federal (STGNF) hospitals in the U.S., and to identify hospital
characteristics that were signiﬁcantly associated with such
changes. METHODS: Using all-payer data from more than 2500
STGNF hospitals, discharge-level drug costs were estimated
using the Medicare Cost Report information on revenue-center-
speciﬁc cost-to-charge ratios applied to the corresponding hos-
pital charges. Cost estimates were analyzed by all DRGs to
identify those in which statistically signiﬁcant (alpha = 0.05)
upward or downward trends were detected. Pharmacy costs 
relative to other hospital costs were also analyzed, as was the
variability across hospitals in case-mix-adjusted average phar-
maceutical cost. Hospital characteristics were evaluated as pre-
dictors of case-mix-adjusted average pharmaceutical costs, and
national estimates of total hospital pharmaceutical costs were
estimated for selected DRG-deﬁned clinical groups. RESULTS:
Numerous DRGs exhibited signiﬁcant upward or downward
trends in average costs per case for pharmaceutical services from
2000 through 2002. Signiﬁcant trends over time in the propor-
tion of total hospital costs that were attributable to pharmaceu-
tical services were also detected. Extensive variability across
hospitals was detected in both the total costs that were due to
pharmaceutical services, as well as the proportion of the total
costs that were due to pharmaceutical services. Many DRGs
exhibited substantial increases in the average dollar amount of
costs for drug treatment from 2000 through 2002. CON-
CLUSIONS: Inpatient costs for pharmaceutical services have
increased substantially in recent years relative to other hospital
services areas, such as laboratory and diagnostic radiology.
Further, there exists extensive variability in the intensity of phar-
maceutical services that are provided, even after case-mix adjust-
ment. Finally, numerous hospital characteristics, such as teaching
status and size, are signiﬁcantly correlated with the relative 
utilization of pharmaceutical services for the treatment of 
inpatients.
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PREVALENCE OF DRUG-RELATED PROBLEMS AMONGST
HOSPITALISED PATIENTS ON POLYPHARMACY IN
SINGAPORE
Koh Y1, Fatimah MK2, Li SC1
1National University of Singapore, Department of Pharmacy,
Singapore, Singapore; 2Alexandra Hospital, Singapore
OBJECTIVE: To investigate the occurrence of all drug-related
problems (DRPs) amongst hospitalised patients on polyphar-
macy, and to conﬁrm the association of advanced age and the
female gender with adverse drug reactions (ADRs). METHODS:
A retrospective, cross-sectional study was carried out in patients
on polypharmacy (5 and more drugs). Chi-square test was used
to test for signiﬁcant differences (p < 0.05) between the age and
gender of patients, and their risk of developing DRPs. A two-
tailed, unpaired t-test was employed to test for signiﬁcant dif-
ference (p < 0.05) between the number of medications taken and
the risk of DRPs. Relative risk (RR) analysis was performed for
geriatric (patients above 65 years old) and female patients to
assess their propensity in developing ADRs. RESULTS: The
study population consisted of 347 patients (43% female), aged
16–97 (average 66 years). Geriatrics made up 58.2% of this pop-
ulation. The number of medications per patient ranged from 5
to 14 (mean 7.4 ± 2.1). The types of DRPs identiﬁed included:
inappropriate treatment (42.9%); potential drug interactions
(45.0%); inappropriate dosages (20.7%); unsafe drugs for
patients (13.5%); ADRs (7.5%). There were no statistical cor-
relations when age and gender were compared between patients
with and without DRPs. However, number of medications taken
was a risk factor for the presence of DRPs (p = 0.001). RR for
geriatrics and female patients to develop ADRs are found to be
1.01 (95% CI: 0.52, 1.85) and 0.79 (95% CI: 0.40, 1.55),
respectively. CONCLUSION: Our results established that DRPs
in hospitalised patients on polypharmacy in Singapore is com-
parable to that in other developed countries. Our results also
support that polypharmacy is a greater risk factor than age
where high susceptibility for DRPs, especially ADRs is con-
cerned. The low RR of geriatrics and female patients developing
ADRs deviates from published results and may be confounded
by our inclusion criteria.
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COMPARING THE COSTS OF MAIL ORDER AND 
RETAIL PHARMACY
Carroll NV1, Brusilovsky I2,York B2, Oscar R2
1Virginia Commonwealth University, Richmond,VA, USA; 2Rx-EOB,
Richmond,VA, USA
OBJECTIVE: To compare the costs of prescriptions dispensed
through mail order and retail pharmacies. We examined total
costs, costs to health plan sponsors, and costs to health plan
members. METHODS: We compared the actual cost of pre-
scriptions dispensed through a mail order pharmacy with what
those same prescriptions would have cost if dispensed through
retail pharmacies. We based our analysis on prescription claims
submitted to a health plan in the northeastern United States
between July 1, 2002 and June 30, 2003. The plan covered about
100,000 members. The plan used a mail-order pharmacy that
was not owned by a major PBM, a 3-tier beneﬁt design, and
speciﬁed that patients’ could get a 90-day supply through mail
order for the equivalent of two 30-day retail copays. Retail phar-
macies were paid a $2.00 dispensing fee per 30-day supply dis-
pensed. The mail-order pharmacy charged no dispensing fee. 
For brand name drugs, the plan paid AWP less 15% to retail
pharmacies and AWP less 17% to the mail-order pharmacy.
RESULTS: Total costs for the 44,847 prescriptions dispensed
through mail order were $6,401,624. Had these prescriptions
been dispensed at retail, costs would have been $6,902,252.
Ingredient costs were $6,401,624 through mail versus
$6,633,170 at retail. Total costs to the health plan were
$4,726,637 through mail versus $4,417,733 at retail. Member
costs were $1,674,987 through mail versus $2,484,519 at retail.
CONCLUSIONS: Mail order was less expensive overall, but
more expensive to the health plan. The loss of copays in the mail
order plan was greater than the savings on ingredient costs and
dispensing fees.
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Strategies to control the quality and cost of medication use are
largely dependent on the ability to alter selection of medications.
Previous models of prescribing behavior have focused on physi-
cians. In the hospital setting, clinical pharmacists and formulary
committee members are also key players in medication decision-
making. Differences between physicians, formulary committee
members, and clinical pharmacists have not been compared.
Knowledge of these differences could have importance in pre-
dicting the effectiveness of strategies designed to inﬂuence med-
ication use in this setting. OBJECTIVE: The objective of this
study was to describe and compare the opinions of physicians,
clinical pharmacists, and formulary committee members with
respect to key factors that inﬂuence medication prescribing in
community hospitals. METHODS: Physicians, clinical pharma-
cists, and formulary committee members were solicited to 
participate. A trained interviewer administered a standardized
questionnaire designed to elicit opinions of participants regard-
ing the importance of factors thought to inﬂuence the prescrib-
ing of medications. Responses were described using descriptive
statistics, and differences between the groups were determined
by Post hoc analysis. RESULTS: A total of 150 individuals par-
ticipated in the study. Safety, effectiveness, formulary status, and
restrictions on prescribing were considered highly inﬂuential by
all participants. Physicians rated the availability of drug samples,
and personal experience higher (more inﬂuential on prescribing)
than clinical pharmacists and formulary committee members.
Clinical pharmacists and formulary committee members rated
the inﬂuence of recommendations by clinical pharmacists, 
prescribing guidelines, and cost or cost comparisons higher than
physicians. Factors that were drug-related, or that involved
policy-related programs tended to be more inﬂuential than indi-
rect factors. CONCLUSIONS: Those who seek to implement
programs to alter medication use should recognize and employ
factors that are most inﬂuential in the decision-making process.
Further, it may be important to consider differences that exist
between key participants in the medication use process.
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E-COMMERCE ON PHARMACEUTICALS: A POSITIVE TREND
OR A TECHNOLOGICAL DEAMON?
Hatzikou M, Liappis T
Boehringer Ingelheim, Elliniko, Athens, Greece
OBJECTIVE: The concept of e-commerce on pharmaceuticals is
a controversial issue affecting both U.S.A and Europe. This
report will evaluate the beneﬁts and disadvantages of online
pharmacies for consumers, pharmacists, and the pharmaceutical
industry. METHODS: The legal background to online phar-
macies in Europe will be examined in accordance with the 
differential pricing and reimbursement issues of some selected
European countries. The reasons for this phenomenon are going
to be analyzed. The easy access, time saving and privacy are the
main explanations, but what about prices? Is internet an indirect
way of parallel trade in pharmaceuticals? What precautions
should be taken for both patients and companies of e-commerce
in pharmaceuticals? RESULTS: Issues of potential risks to public
health because of handling outside regulated distribution chan-
nels. Additionally, lack of prescription in accordance with arrival
without instructions for proper use or in an incorrect dose might
put the health of the patients in danger. CONCLUSION: The
phenomenon of e-commerce on pharmaceuticals is a “headache”
issue for all the involved parties in the medical world, the doctors
who can’t control their patients medicines, pharmacists who lose
market share, patients who take medicines which in many cases
might cause them side effects because they don’t have the per-
mission of the doctor and last but not least pharmaceutical com-
panies which they can’t control their stocks since patients from
different countries order medicines via internet with lower prices
than they are being sold in their country.
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TRENDS IN APPROVALS BY THE PHARMACEUTICAL
BENEFITS ADVISORY COMMITTEE
Wonder M1, Neville AM2, Parsons R2
1Novartis Pharmaceuticals Australia Pty Ltd, North Ryde, New South
Wales, Australia; 2Pretium (Health Economic Consultants), Sydney,
NSW, Australia
OBJECTIVES: In Australia, drugs are only publicly subsidised
and listed on the Pharmaceutical Beneﬁts Scheme (PBS) if the
Pharmaceutical Beneﬁts Advisory Committee (PBAC) has deter-
mined that the drug is cost effective. This process is in addition
to the regulatory process including the Australian Drug Evalua-
tion Committee (ADEC). Critics of the current scheme have 
commented that requirements of the PBAC have become more
onerous in recent years and that the listing of important new
drugs is being delayed. We sought to analyse all published rec-
ommendations of the PBAC meetings from December 1999 to
June 2003 to determine if there is a relationship between the date
of a drug’s regulatory approval, its PBAC recommendation and
subsequent listing on the PBS. METHODS: There were 4 dates
associated with each application: ADEC meeting date, PBAC
meeting date, projected PBS listing date (the ﬁrst date an
approved drug could be PBS listed) and actual PBS listing date.
We used a logistic regression model to identify variables associ-
ated with successful PBS listing, including the year of the PBAC
meeting, submission type, form of economic analysis and
requested listing restrictions. A second analysis was performed
with the outcome variable being ‘approval within 5 months of
meeting date’, to overcome any bias against 2003 applications
that had a shorter follow-up period. RESULTS: The analysis
showed ‘Year of PBAC meeting’ was statistically signiﬁcant for
successful PBS listing. The other variables were not statistically
signiﬁcant. Using 1999 as the reference year, the odds ratios were
as follows: 2000 = 0.6889, 2001 = 0.5500, 2002 = 0.3917, 2003
= 0.1000. Using the modiﬁed dependent variable (approval
within 5 months) similar results to the above analysis were pro-
duced—the OR for variable Year remained statistically signiﬁ-
cant. CONCLUSIONS: The analysis of factors associated with
PBS listing showed that there was a signiﬁcant downward trend
over the years in successful applications. This trend did not
appear to be associated with the other factors listed.
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PHARMACEUTICAL PRESCRIPTION: COSTS AND FACTORS
OF INFLUENCE 
Akremi J
Laboratory THEMA (Economic Theory, Modelling and Applications),
University Paris X, Paris, Nanterre Cedex, France
OBJECTIVE: In France, for about 30 years, the level of the con-
sumption of pharmacy strongly increased, which increased the
public health insurance expenditure. Policies, who were applied,
increased the costs of the patients. The physicians were blamed
in those drifts. By knowing that the doctor does not have direct
ﬁnancial proﬁts in the recommendation of the pharmacies, we
try to understand if his implication direct or indirect in the
increase of the level of consumption of medication is founded.
This study examines the factors, which inﬂuence the prescription
of medication of the physicians. METHODS: For the empirical
study we used the national base of the data of the French physi-
cians who were observed during the period from 1981 to 2000.
The variables used are the seniority of the physician, the struc-
